Vir Biotechnology and GlaxoSmithKline Expanded Agreement

Vir Biotechnology and GlaxoSmithKline Expanded Collaboration 

Vir Biotechnology (VIR) and GlaxoSmithKline plc (GSK) announced the signing of a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.

The Expanded Collaboration

This new collaboration builds on a 2020 agreement to research and develop therapies for coronaviruses and provides GlaxoSmithKline exclusive rights to collaborate with Vir Biotechnology on the development of potential best-in-class monoclonal antibodies (mAbs) for the prevention or treatment of influenza.

VIR-2482 

VIR-2482 – an intramuscularly administered investigational mAb designed as a universal prophylactic for influenza A. This antibody has completed a Phase 1 trial, as well as next-generation antibodies for the prevention or treatment of influenza during a three-year research period.

Leave a Reply